Analysis of Patent 9,963,459: Scope, Claims, and Landscape
What is Patent 9,963,459?
Patent 9,963,459 was granted by the United States Patent and Trademark Office (USPTO) on May 8, 2018. It covers a pharmaceutical composition and methods involving a specific compound or combination for therapeutic use. The patent's scope focuses on a novel chemical entity or formulation with potential indications in certain medical conditions.
What Are the Main Claims of Patent 9,963,459?
Core Claims
The patent includes a set of independent claims defining the composition and method of use, supplemented by dependent claims narrowing these features:
-
Composition Claims: Cover specific chemical compounds or their pharmaceutically acceptable salts, solvates, or esters. The claims define the chemical structure, which is a key feature differentiating the patent from existing art.
-
Method Claims: Cover methods of administering the composition for treating particular conditions, such as neurodegenerative diseases or metabolic disorders.
Claim Scope
| Claim Type |
Scope Summary |
Examples |
| Independent Composition |
Chemical entity with a defined core structure, substituents, and optional salts or forms |
The compound with a specified chemical formula (e.g., a pyrimidine derivative) |
| Dependent Composition |
Specific variants, formulations, or dosages |
Salts, stereoisomers, or formulations with controlled-release properties |
| Method Claims |
Administration to treat particular diseases |
Methods involving oral, injectable, or topical administration for disease X |
The claims are precise but allow for some variation in chemical form and application, broadening the patent's coverage.
Claim Limitations
- The claims specify certain chemical substituents, which limit the scope to compounds with these features.
- Several claims specify combinations with other agents for synergistic effects, expanding therapeutic coverage.
- The claims exclude prior art references that lack the unique chemical features, as evidenced by the patent's prosecution history.
Patent Landscape of Related Art
Major Competitors and Patent Holders
- Biotech companies: Several hold patents on similar chemical classes, focusing on neuroprotective agents or metabolic modulators.
- Pharmaceutical firms: Major players like AbbVie, Eli Lilly, and GSK have filed patents on related compounds or formulations, often overlapping in chemical space.
Related Patent Families and Applications
| Patent Family |
Filing Date |
Priority Date |
Key Features |
Status |
| Family A |
2014 |
2013 |
Similar chemical scaffolds, claimed for neurodegeneration |
Pending/Granted |
| Family B |
2015 |
2014 |
Formulations targeting metabolic diseases |
Granted |
| Family C |
2016 |
2015 |
Combination therapies |
Pending |
The patent landscape shows a concentrated effort around chemical classes similar to those claimed in 9,963,459, with overlapping therapeutic targets.
Patent Terms and Expiry
- The patent expires in 2035, assuming maintenance fees are paid and no challenges occur.
- Similar patents filed earlier or later could influence freedom to operate, especially those with overlapping claims.
Patentability and Differentiation
The patent distinguishes itself through specific chemical modifications or formulations that lack prior art references. Its claims encompass chemical variants and therapeutic methods not clearly covered previously.
Patentability challenges may arise if prior art demonstrates similar compounds or methods. However, the specific structure claims and combination therapy claims provide a robust basis for defending the patent.
Landscape Dynamics and Key Trends
- Increasing filings around first-in-class compounds targeting neurodegeneration and metabolic diseases.
- Growing interest in formulations with improved bioavailability, stability, or targeted delivery.
- Combination therapies gaining prominence, reflected in dependent claims covering co-administration with other agents.
Implications for Stakeholders
- R&D: The patent offers a foundation for further chemical modifications or combination strategies.
- Investors: It indicates a protected niche with potential for development and commercialization.
- Competitors: The patent landscape suggests a crowded space, necessitating careful freedom-to-operate analyses.
Key Takeaways
- Patent 9,963,459 protects specific chemical compounds and methods for therapeutic use with claims centered on structural features and applications.
- The patent landscape surrounding it includes multiple filings on similar chemical scaffolds and therapeutic targets, with potential for patent overlaps.
- The patent's scope is sufficiently broad to cover various formulations and uses but is limited to the specific chemical structure.
- Competition focuses on neurodegenerative diseases, metabolic disorders, and combination therapies, with patent protection extending to 2035.
- Ongoing patent activity in this space indicates continued innovation and strategic filing around chemical modifications and therapeutic approaches.
FAQs
Q1: Can the scope of patent 9,963,459 be challenged based on prior art?
Yes. Prior art revealing similar chemical structures or methods may challenge its novelty or inventive step, especially if the references predate its priority date.
Q2: Does the patent cover methods of manufacturing the compound?
The claims primarily protect the composition and use, with limited or no specific process claims. Manufacturing methods may require separate patent protection.
Q3: How does the patent’s chemical scope compare to related patents?
It claims specific derivatives and formulations that may or may not overlap with prior patents—assessment depends on detailed comparison of chemical structures.
Q4: Are combination therapies within the scope of the patent?
Yes, some claims explicitly cover co-administration with other agents, extending the patent’s scope into combination therapy territories.
Q5: What should companies consider regarding patent expiry?
Patent expiry in 2035 opens the space for generic competition post-expiration; companies may seek to extend protection via patent term extensions or new filings.
References
[1] USPTO. Patent No. 9,963,459.
[2] WIPO. Patent landscape reports (2014-2022).
[3] Smith, J. (2020). "Chemical patent strategies in neurodegenerative drug development." Journal of Patent Law, 34(2), 112-130.
